Device Trial Radar · NCT04660344
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
761
Actual
Start
May 3, 2021
Primary completion
Jun 15, 2025
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Natera, Inc.
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.
Conditions
- Muscle-invasive Bladder Cancer
Interventions
AtezolizumabDrug
ctDNA positive participants will receive 1680 mg IV, every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
PlaceboOther
ctDNA positive participants will receive placebo IV, Q4W on Day 1 of each 28-day cycle
SignateraDevice
Signatera will be used to evaluate whether ctDNA is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter surveillance follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- INV-assessed Disease-free Survival (DFS)Time frame: From randomization to the first occurrence of a DFS event (Up to 48.2 months)
Locations
140 sites in 23 countries. Site status is shown where the registry gives one.
Cancer Care Centers of Brevard
Rockledge, Florida
Cleveland Clinic
Cleveland, Ohio
AHN Cancer Institute ? Allegheny General Hospital
Pittsburgh, Pennsylvania
137 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.